- CSPC Pharma’s revenue for the first quarter beat estimates.
- The revenue reached a total of 8.98 billion yuan, surpassing the estimated 7.44 billion yuan.
- This estimation was based on two separate estimates.
- Sales of finished drugs that were sold externally contributed to this revenue, equalling 7.56 billion yuan.
- The company’s overall performance instilled confidence among investors, with 32 buys.
- There were slightly more circumspect attitudes as well, with 3 holds and 1 sell recorded.
CSPC Pharmaceutical Group on Smartkarma
Analyst coverage of CSPC Pharmaceutical Group on Smartkarma has been favorable, with analyst Tina Banerjee providing a bullish sentiment on the company. In her research report titled “CSPC Pharmaceutical (1093 HK): Deep Value High Dividend Yield Idea; New Launches to Drive Growth,” Banerjee highlights CSPC Pharmaceutical’s steady growth in finished drugs in 2023, driven by new products. The company’s plan to launch 50 innovative drugs in the next 5 years is expected to sustain this growth. Notably, CSPC Pharmaceutical’s shares are trading at a low P/E ratio of 11.3x, the lowest in the past five years, making them cheaper than peers. Additionally, the company offers an attractive dividend yield of over 4%, adding to its investment appeal.
A look at CSPC Pharmaceutical Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores for CSPC Pharmaceutical Group, the company shows promising long-term potential. With a strong focus on dividends and growth, CSPC Pharmaceutical Group demonstrates stability and potential for expansion in the pharmaceutical market. Its resilience score further solidifies its position, indicating a capacity to weather market fluctuations. While momentum is slightly lower, the overall outlook remains positive for CSPC Pharmaceutical Group.
CSPC Pharmaceutical Group Limited, a pharmaceutical company known for manufacturing and selling a variety of products such as vitamin C, antibiotics, and generic drugs, stands out for its commitment to innovation. Engaged in both traditional drug manufacturing and the development of cutting-edge medications, the company’s diverse portfolio positions it well for sustained growth and success in the competitive pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
